Download PDF
Fortschr Neurol Psychiatr 2012; 80(3): 167-179
DOI: 10.1055/s-0031-1299095
Fort- und Weiterbildung

© Georg Thieme Verlag KG Stuttgart · New York

Botulinumtoxin in der klinischen Neurologie

Botulinum Toxin in Clinical NeurologyJ. Wissel1 , F. Kempf1
  • 1Neurologische Rehabilitationsklinik Beelitz-Heilstätten
Further Information

Publication History

Publication Date:
09 March 2012 (online)

    Permissions and Reprints

Lernziele

Der vorliegende Artikel gibt einen aktuellen Überblick über die bestehenden Indikationen mit erwiesener Wirksamkeit der Behandlung mit Botulinum-Neurotoxin Typ A (BoNT-A) sowie über Empfehlungen zur praktischen Anwendung von BoNT-A. Der Leser verfügt nach der Lektüre über Kenntnisse zur Indikationsstellung, Durchführung und Evaluation der Behandlung.

Literatur

  • 1 Jahn R. Neuroscience. A neuronal receptor for botulinum toxin.  Science. 2006;  312 540-541
    Google Scholar
  • 2 Kessler K R, Benecke R. The EBD test – a clinical test for the detection of antibodies to botulinum toxin type A.  Mov Disord. 1997;  12 95-99
    Google Scholar
  • 3 Muller K, Mix E, Adib Saberi F et al. Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity.  J Neural Transm. 2009;  116 579-585
    Google Scholar
  • 4 Yablon S A, Brashear A, Gordon M F et al. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials.  Clin Ther. 2007;  29 683-690
    Google Scholar
  • 5 Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc.  Eur J Neurol. 2006;  13 (Suppl 1) 11-15
    Google Scholar
  • 6 Borodic G. Therapeutic botulinum toxin.  Lancet. 1994;  344 1370
    Google Scholar
  • 7 Gracies J M, Lugassy M, Weisz D J et al. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study.  Arch Phys Med Rehabil. 2009;  90 9-16
    Google Scholar
  • 8 Barnes M, Schnitzler A, Medeiros L et al. Efficacy and safety of NT 201 for upper limb spasticity of various etiologies – a randomized parallel-group study.  Acta Neurol Scand. 2010;  122 295-302
    Google Scholar
  • 9 Francisco G E, Boake C, Vaughn A. Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques.  Am J Phys Med Rehabil. 2002;  8 355-363
    Google Scholar
  • 10 Gracies J M, Lugassy M, Weisz D J et al. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study.  Arch Phys Med Rehabil. 2009;  90 9-16
    Google Scholar
  • 11 Molloy F M, Shill H A, Kaelin-Lang A et al. Accuracy of muscle localization without EMG: implications for treatment of limb dystonia.  Neurology. 2002;  58 805-807
    Google Scholar
  • 12 Chin T Y, Graham H K. Botulinum toxin A in the management of upper limb spasticity in cerebral palsy.  Hand Clin. 2003;  19 591-600
    Google Scholar
  • 13 Yang E J, Rha D W, Yoo J K et al. Accuracy of manual needle placement for gastrocnemius muscle in children with cerebral palsy checked against ultrasonography.  Arch Phys Med Rehabil. 2009;  90 741-744
    Google Scholar
  • 14 Berweck S, Schroeder A S, Fietzek U M et al. Sonographyguided injection of botulinum toxin in children with cerebral palsy.  Lancet. 2004;  363 249-250
    Google Scholar
  • 15 Berweck S, Wissel J. Sonographic imaging for guiding botulinum toxin injections in limb muscles.  Adv Clin Neurosci Rehab. 2004;  4 28-31
    Google Scholar
  • 16 Berweck S, Heinen F. Use of botulinum toxin in pediatric spasticity (cerebral palsy).  Mov Disord. 2004;  19 162-167
    Google Scholar
  • 17 Fietzek U M, Schroeder A S, Wissel J et al. Split-screen video demonstration of sonography-guided muscle identification and injection of botulinum toxin.  Mov Disord. 2010;  25 2225-2228
    Google Scholar
  • 18 Ashford S, Turner-Stokes L. Goal attainment for spasticity management using botulinum toxin.  Physiother Res Int. 2006;  11 24-34
    Google Scholar
  • 19 Wissel J, Ward A B, Erztgaard P et al. European consensus table on the use of botulinum toxin type A in adult spasticity.  J Rehabil Med. 2009;  41 13-25
    Google Scholar
  • 20 Wissel J, auf dem Brinke M, Hecht M et al. Botulinum-Neurotoxin in der Behandlung der Spastizität im Erwachsenenalter.  Nervenarzt. 2011;  82 481-495
    Google Scholar
  • 21 Kanovský P, Slawek J, Denes Z et al. Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity.  Clin Neuropharmacol. 2009;  32 259-65
    Google Scholar
  • 22 Kaňovský P, Slawek J, Denes Z et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity.  J Rehabil Med. 2011;  43 486-492
    Google Scholar
  • 23 Elovic E P, Brashear A, Kaelin D et al. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients.  Arch Phys Med Rehabil. 2008;  89 799-806
    Google Scholar
  • 24 Bakheit A M, Fedorova N V, Skoromets A et al. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles.  J Neurol Neurosurg Psychiatry. 2004;  75 1558-1561
    Google Scholar
  • 25 Mohammadi B, Balouch S A, Dengler R et al. Long-term treatment of spasticity with botulinum toxin type A: an analysis of 1221 treatments in 137 patients.  Neurol Res. 2010;  32 309-313
    Google Scholar
  • 26 Gordon M F, Brashear A, Elovic E et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke.  Neurology. 2004;  63 1971-1973
    Google Scholar
  • 27 Lagalla G, Danni M, Reiter F et al. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb.  Am J Phys Med Rehabil. 2000;  79 377-384
    Google Scholar
  • 28 Sutherland D H, Kaufman K R, Wyatt M P et al. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy.  Gait Posture. 1999;  10 1-9
    Google Scholar
  • 29 Ubhi T, Bhakta B B, Ives H L et al. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy.  Arch Dis Child. 2000;  83 481-487
    Google Scholar
  • 30 Baker R, Jasinski M, Maciag-Tymecka I et al. Botulinum toxin treatment of spasticity in diplegic cerebral palsy: a randomized, double-blind, placebo-controlled, dose-ranging study.  Dev Med Child Neurol. 2002;  44 666-675
    Google Scholar
  • 31 Koman L A, Mooney 3 rd J F, Smith B P et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebocontrolled trial. BOTOX Study Group.  J Pediatr Orthop. 2000;  20 108-115
    Google Scholar
  • 32 Wissel J, Heinen F, Schenkel A et al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of „high-dose“ versus „lowdose“ treatment.  Neuropediatrics. 1999;  30 120-124
    Google Scholar
  • 33 Polak F, Morton R, Ward C et al. Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy.  Dev Med Child Neurol. 2002;  44 551-555
    Google Scholar
  • 34 Heinen F, Desloovere K, Schroeder A S et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy.  Eur J Paediatr Neurol. 2010;  14 45-66
    Google Scholar
  • 35 Hägglund G, Andersson S, Düppe H et al. Prevention of severe contractures might replace multilevel surgery in cerebral palsy: results of a population-based health care program and new techniques to reduce spasticity.  J Pediatr Orthop B. 2005;  14 269-273
    Google Scholar
  • 36 Naumann M, Albanese A, Heinen F et al. Safety and efficacy of botulinum toxin type A following long-term use.  Eur J Neurol. 2006;  13 (Suppl 4) 35-40
    Google Scholar
  • 37 Schramm A, Ndayisaba J, auf dem Brinke M et al. Therapie der Spastik mit onabotulinumtoxin A – erweiterte praktische Erfahrungen in 10 spezialisierten deutschen Zentren.  Aktuelle Neurologie. 2011;  38 99-110
    Google Scholar
  • 38 Simpson D M, Blitzer A, Brashear A et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.  Neurology. 2008;  70 1699-1706
    Google Scholar
  • 39 Poewe W, Deuschl G, Nebe A et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group.  J Neurol Neurosurg Psychiatry. 1998;  64 13-17
    Google Scholar
  • 40 Brans J W, Lindeboom R, Snoek J W et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial.  Neurology. 1996;  46 1066-1072
    Google Scholar
  • 41 Benecke R, Jost W H, Kanovsky P et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia.  Neurology. 2005;  64 1949-1951
    Google Scholar
  • 42 Brashear A, Hogan P, Wooten-Watts M et al. Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia.  Advances in Therapy. 2005;  22 49-55
    Google Scholar
  • 43 Haussermann P, Marczoch S, Klinger C et al. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.  Movement Disorders. 2004;  19 303-308
    Google Scholar
  • 44 Truong D, Brodsky M, Lew M et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.  Parkinsonism Relat Disord. 2010;  16 316-323
    Google Scholar
  • 45 Mohammadi B, Buhr N, Bigalke H et al. A long-term follow-up of botulinum toxin A in cervical dystonia.  Neurol Res. 2009;  31 463-466
    Google Scholar
  • 46 Reichel G, Stenner A, Jahn A. Zur Phänomenologie der zervikalen Dystonien.  Fortschr Neurol Psychiatr. 2009;  77 272-277
    Google Scholar
  • 47 Roggenkämper P, Jost W H, Bihari K et al. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm.  J Neural Transm. 2006;  113 303-312
    Google Scholar
  • 48 Jankovic J, Comella C, Hanschmann A et al. Efficacy and safety of incobotulinumtoxin A in the treatment of blepharospasm – A randomized trial.  Mov Disord. 2011;  26 1521-1528
    Google Scholar
  • 49 Wabbels B, Reichel G, Fulford-Smith A et al. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm.  J Neural Transm. 2011;  118 233-239
    Google Scholar
  • 50 Mejia N I, Vuong K D, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity.  Mov Disord. 2005;  20 592-597
    Google Scholar
  • 51 Hsiung G Y, Das S K, Ranawaya R et al. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.  Mov Disord. 2002;  17 1288-1293
    Google Scholar
  • 52 Bentivoglio A R, Fasano A, Ialongo T et al. Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs.  Neurotox Res. 2009;  15 224-231
    Google Scholar
  • 53 Truong D, Comella C, Fernandez H H et al. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial.  Parkinsonism Relat Disord. 2008;  14 407-414
    Google Scholar
  • 54 Albanese A, Bentivoglio A R, Colosimo C et al. Pretarsal injections of botulinum toxin improve blepharospasm in previously unresponsive patients.  J Neurol Neurosurg Psych. 1996;  60 693-694
    Google Scholar
  • 55 Jankovic J, Schwartz K, Clemence W et al. A randomized, double-blind, placebocontrolled study to evaluate botulinum toxin type A in essential hand tremor.  Mov Disord. 1996;  11 250-256
    Google Scholar
  • 56 Brin M F, Lyons K E, Doucette J et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor.  Neurology. 2001;  56 1523-1528
    Google Scholar
  • 57 Naumann M, So Y, Argoff C E et al. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.  Neurology. 2008;  70 1707-1714
    Google Scholar
  • 58 Naumann M, Lowe N J. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial.  BMJ. 2001;  323 596-599
    Google Scholar
  • 59 Heckmann M, Ceballos-Baumann A O, Plewig G. Botulinum toxin A for axillary hyperhidrosis (excessive sweating).  N Engl J Med. 2001;  344 488-493
    Google Scholar
  • 60 Lipp A, Trottenberg T, Schink T et al. A randomized trial of botulinum toxin A for treatment of drooling.  Neurology. 2003;  61 1279-1281
    Google Scholar
  • 61 Aurora S K, Dodick D W, Turkel CC et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.  Cephalalgia. 2010;  30 793-803
    Google Scholar
  • 62 Diener H C, Dodick D W, Aurora S K et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.  Cephalalgia. 2010;  30 804-814
    Google Scholar
  • 63 Blumenfeld A, Silberstein S D, Dodick D W et al. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program.  Headache. 2010;  50 1406-1418
    Google Scholar
  • 64 Dykstra D D, Sidi A A. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study.  Arch Phys Med Rehabil. 1990;  71 24-26
    Google Scholar
  • 65 Seze de M, Petit H, Gallien P et al. Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease.  Eur Urol. 2002;  42 56-62
    Google Scholar

Prof. Dr. med. Jörg Wissel

Neurologische Rehabilitationsklinik Beelitz-Heilstätten

Paracelsusring 6a

14547 Beelitz-Heilstätten

Email: joerg@schwarz-wissel.de

      >